Composition comprising B regulatory cells
AssigneeOxford University Innovation Limited
InventorsKathryn J. Wood, Sushma Shankar
Life of this patent
Estimating the term…
Abstract
The present invention relates to an expanded population of human Breg cells having the phenotype CD19+CD73−CD71+CD25+TIM-1+ and methods for producing the cell population of the invention. The invention also relates to pharmaceutical compositions comprising the cell populations of the invention and their use in the treatment of immune-mediated disorders.
Claims20
An isolated population of cells, wherein the population comprises human Breg cells, having the phenotype CD19+CD73−CD71+CD25+TIM-1+, and wherein the human Breg cells additionally have the phenotype CD154+.
A method for producing a human Breg cell population comprising:
- isolating human CD19+ B cells;
- culturing said CD19+ B cells in the presence of CD154, or peptide fragments thereof, and/or cells expressing CD154, and at least one cytokine or growth factor for at least 3 days;
- harvesting the Breg cells so produced.
An expanded human Breg cell population obtained by
- isolating human CD19+ B cells,
- culturing said CD19+ B cells in the presence of cells expressing CD154 at a ratio of 1:1, and at least one cytokine or growth factor for at least 3 days, and
- harvesting the Breg cells so produced.
Dependencies are inferred from the claim text.